Find in Library

The plasminogen activator inhibitor-1 (<i>PAI-1</i>) is expressed in many cancer cell types and modulates cancer growth, invasion, and angiogenesis. The present study investigated the association between five <i>PAI-1</i> gene polymorphisms and colorectal cancer (CRC) risk. Five <i>PAI-1</i> polymorphisms (−844G > A [rs2227631], −675 4G > 5G [rs1799889], +43G > A [rs6092], +9785G > A [rs2227694], and +11053T > G [rs7242]) were genotyped using a polymerase chain reaction-restriction fragment length polymorphism assay in 459 CRC cases and 416 controls. Increased CRC risk was more frequently associated with <i>PAI-1</i> −675 5G5G polymorphism than with 4G4G (adjusted odds ratio (AOR) = 1.556; 95% confidence interval (CI): 1.012–2.391; <i>p</i> = 0.04). In contrast, for the <i>PAI-1</i> +11053 polymorphism, we found a lower risk of CRC with the GG genotype (AOR = 0.620; 95% CI: 0.413–0.932; <i>p</i> = 0.02) than with the TT genotype, as well as for recessive carriers (TT + TG vs. GG, AOR = 0.662; 95% CI: 0.469–0.933; <i>p</i> = 0.02). The +43AA genotype was associated with lower overall survival (OS) than the +43GG genotype. Our results suggest that the <i>PAI-1</i> genotype plays a role in CRC risk. This is the first study to identify an association between five <i>PAI-1</i> polymorphisms and CRC incidence worldwide.